Gauss, a computer vision technology company, has created a rapid COVID-19 antigen test that people can self-administer at home and uses an AI-powered smartphone app to process results within minutes – without the need for labs or a healthcare provider, according to a press release.
Ro, a telehealth company, will begin nationwide distribution of Gauss’s tests pending emergency use authorization (EUA) of the test from the U.S. Food and Drug Administration. Ro said it will not only deliver the tests to patients’ homes, but it will also offer patients support from healthcare providers on its platform to understand or ask questions about their results.
The test, which Gauss developed in partnership with Cellex, a biotechnology company specializing in rapid diagnostics, is powered by a smartphone app developed by Gauss.
